Chimerix
dose increasing to more frequent dosing no observed with weekly dosing in data indicates correlation between exposure time and tumor cell viability more frequent dosing schedule designed to increase duration of target exposure most common treatment | Chimerix
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
35 of 43
Related slides by other companies
Ocuphire Pharma
Investor Presentation
May 2023
profile overview well tolerated oral dose up to day twice daily dosing progression of diabetic minimal ocular side effects ire cine | Ocuphire Pharma
Alkermes
Investor Presentation
October 2023
complete response in year old patient with platinum resistant ovarian cancer | Alkermes
argenx SE
Results
March 2022
immune thrombocytopenia advance trials two run in parallel and | argenx SE
argenx SE
Results
May 2021
phase advance two trials run in parallel it | argenx SE
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io